Virtual Tumor Board: Optimizing Personalized Care Plans for Patients With Advanced Soft Tissue Sarcoma

STATEMENT OF NEED

Soft tissue sarcomas are a heterogeneous group of malignancies that arise primarily from the mesodermal tissues of the extremities, trunk and retroperitoneum, and head and neck. An estimated 13,130 new cases are diagnosed in the United States annually and 5,350 people die of the disease. Surgical resection is the mainstay of treatment for localized soft tissue sarcoma, with radiation and chemotherapy commonly used as adjuncts. However, nearly 50% of patients will experience locoregional recurrence, distant metastases, or both. The outlook for those with unresectable and metastatic disease is poor, with median overall survival in the order of 1 year.

TARGET AUDIENCE

Medical oncologists, surgical oncologists, radiation oncologists, pathologists, oncology advanced practitioners, oncology nurses, and other health care professionals involved in the treatment of patients with soft tissue sarcoma.

LEARNING OBJECTIVES

Upon completion of this activity, participants should be able to:

1.) Distinguish patient and tumor characteristics that can inform personalized therapeutic approaches in soft tissue sarcoma
2.) Evaluate the clinical relevance of emerging data in the management of advanced soft tissue sarcoma
3.) Assess strategies to manage adverse events and optimize treatment outcomes of patients with advanced soft tissue sarcoma